Phosphorylation of IRS1 at serine 307 in response to insulin in human adipocytes is not likely to be catalyzed by p70 ribosomal S6 kinase

• Published in: PloS one 2013-04, Vol.8 (4), p.e59725-e59725
• Main Authors: Rajan, Meenu Rohini, Fagerholm, Siri, Jönsson, Cecilia, Kjølhede, Preben, Turkina, Maria V, Strålfors, Peter
• Format: Article
• Language: English
• Subjects: Adenoviruses; Adipocytes; Adipocytes - drug effects; Adipocytes - metabolism; Amino Acid Sequence; Analysis; Biology; Catalysis; Cellular signal transduction; Control theory; Diabetes; Diabetes mellitus; Ethics; Fat cells; Feedback; Feedback loops; Humans; Imidazoles - pharmacology; Inhibitors; Insulin; Insulin - pharmacology; Insulin Receptor Substrate Proteins - chemistry; Insulin Receptor Substrate Proteins - metabolism; Insulin resistance; Kinases; MEDICIN; MEDICINE; Molecular Sequence Data; Musculoskeletal system; Mutation; Pathogenesis; Peptides - chemistry; Phosphorylation; Phosphorylation - drug effects; Physiology; Piperazines - pharmacology; Protein kinase; Proteins; Rapamycin; Ribosomal protein S6; Ribosomal protein S6 kinase; Ribosomal Protein S6 Kinases, 70-kDa - antagonists & inhibitors; Ribosomal Protein S6 Kinases, 70-kDa - genetics; Ribosomal Protein S6 Kinases, 70-kDa - metabolism; Serine; Serine - metabolism; Signaling; Substrates; Surgery; TOR protein; TOR Serine-Threonine Kinases - antagonists & inhibitors; TOR Serine-Threonine Kinases - metabolism; Tyrosine
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0059725

The insulin receptor substrate-1 (IRS1) is phosphorylated on serine 307 (human sequence, corresponding to murine serine 302) in response to insulin as part of a feedback loop that controls IRS1 phosphorylation on tyrosine residues by the insulin receptor. This in turn directly affects downstream signaling and is in human adipocytes implicated in the pathogenesis of insulin resistance and type 2 diabetes. The phosphorylation is inhibited by rapamycin, a specific inhibitor of mammalian target of rapamycin (mTOR) in complex with raptor (mTORC1). The mTORC1-downstream p70 ribosomal protein S6 kinase (S6K1), which is activated by insulin, can phosphorylate IRS1 at serine 307 in vitro and is considered the physiological protein kinase. Because the IRS1 serine 307-kinase catalyzes a critical step in the control of insulin signaling and constitutes a potential target for treatment of insulin resistance, it is important to know whether S6K1 is the physiological serine 307-kinase or not. We report that, by several criteria, S6K1 does not phosphorylate IRS1 at serine 307 in response to insulin in intact human primary adipocytes: (i) The time-courses for phosphorylation of S6K1 and its phosphorylation of S6 are not compatible with the phosphorylation of IRS1 at serine 307; (ii) A dominant-negative construct of S6K1 inhibits the phosphorylation of S6, without effect on the phosphorylation of IRS1 at serine 307; (iii) The specific inhibitor of S6K1 PF-4708671 inhibits the phosphorylation of S6, without effect on phosphorylation of IRS1 at serine 307. mTOR-immunoprecipitates from insulin-stimulated adipocytes contains an unidentified protein kinase specific for phosphorylation of IRS1 at serine 307, but it is not mTOR or S6K1.